To stop cancer: Block its messages

March 30, 2015, Weizmann Institute of Science
Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated. Credit: Weizmann Institute of Science

The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions are made. But this rapid, long-distance communication system leaves itself open to mutations that can give rise to a "spam attack" that promotes cancer. Prof. Rony Seger of the Weizmann Institute's Biological Regulation Department and his team have now proposed a method of shutting off the overflow of information before it can get to the nucleus. If the initial promising results hold up, the method could be used to treat a number of different cancers, especially several that develop resistance to current treatments, and it might possibly induce fewer side effects than those treatments do.

These findings appeared today in Nature Communications.

Since don't have electronic communication, they use proteins; and they generally manage to send messages quite ably, even getting them through the membranes surrounding the cells and those around the distant nucleus to which the information must ultimately be delivered. A directive from outside the cell - for example a growth factor molecule telling the cell to divide - stops at the cellular membrane. A receptor on the membrane's outer surface accepts the message and passes its signal to the inner side. From there, "if the molecules were human messengers, they would have to transverse the equivalent of some 70 km to get from the to the nucleus," says Seger. Instead of sending messages all the way by a single courier molecule, the cell speeds things up with a sort of relay in which the message gets handed from one molecule to another. This whole membrane-to-nucleus communications system is known as a , and there are about 15 different pathways for transferring the cell's main internal messaging.

Seger has identified a number of the proteins involved in these pathways, especially in one particular pathway, called the MAPK/ERK cascade, which is involved in . Dysregulation of this pathway shows up in some 85% of all cancer types. In normal cells, the messages these proteins pass along are normally delivered in spikes: The last protein in the relay slips into the cell nucleus, delivers the memo, and slips out again. But following certain mutations, the previously useful message becomes spam: It gets sent over and over, flooding the nucleus's "inbox." The response to this "spam attack" can be disastrous; in the case of such messages as those to grow or divide, the result may be cancerous.

A crucial step in this pathway takes place when a molecule called ERK undergoes a transformation that enables it to pass through the membrane surrounding the nucleus. Seger has researched this step in depth, revealing an entire, complex process that must occur for ERK to get its message across.

Seger realized that an effective nuclear "spam filter" on the ERK pathway would involve blocking just this step, thus preventing specific ERKs' "messages" from getting into the nucleus. He and his group, including Alexander Plotnikov, Karen Flores and Galia Maik-Rachline, designed a variety of small molecules to enter the cell and block the transfer of ERK molecules into the cell's nucleus. Working with Dr. Michal Besser of the Sheba Medical Center, they grew cells from different cancers in culture and then added the different molecules to see which of them would best target ERK.

The team identified one potential drug molecule that performed quite well, even causing many of the cancer cells to die. Seger says that the cancer cells become "addicted" to the constant flow of ERK signals, so adding a filter that cuts this signal off causes them to die. Importantly, this molecule did not affect normal cells, suggesting that it mainly targets the cancer process and therefore might have fewer side effects than the present chemotherapy drugs.

The next step was to test the molecule in mouse models of human cancers. In some of the cancers, says Seger, "the molecule worked even better in the animal models than it did in culture. The cancers disappeared within days and did not return." In addition, the fact that the molecules do not destroy the ERK but only stop it from entering the nucleus may be good news for healthy cells: The ERK can still send a "delivery receipt" back up the relay to the receptors, so they don't try to resend the message.

One of the cancers that the molecule eradicated in the experiments was melanoma, an often fatal cancer with few available treatments. The drugs currently used for melanoma, says Seger, usually work for a while and then the cancer becomes resistant to them. He envisions the new molecule being added to the drug regimen, in rotation with others so that resistance cannot develop. All in all, the molecule was completely effective in eliminating around a dozen of the cancers the team tested, and many others showed a decline, if not complete destruction, of the .

The method of designing small molecules that can get inside cells and stop certain messages before they become "spam" might be useful in treating other diseases, in addition to cancer. "Every pathway is associated with a different disease," says Seger. "The trick is to find the molecules that can selectively target just one stage in the process." He and his team are currently experimenting with to block a different pathway, one that is associated with autoimmune disease.

Explore further: Cancer: Kill the messenger

Related Stories

Cancer: Kill the messenger

June 12, 2012
A small molecule developed at the Weizmann Institute prevents a cancer-causing message from entering the cell nucleus.

Genetic modification aids cancer drug discovery

March 4, 2015
Genetically modifying cancer cells can aid in clarifying new cancer drugs' mechanism of action, according to a new study by researchers at KU Leuven's Laboratory of Virology and Chemotherapy (Rega Institute).

Preclinical study indicates potential for novel inhibitor to overcome drug resistance induced by RAF, MEK inhibitors

April 8, 2013
A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, ...

Do salamanders hold the key to limb regeneration?

June 19, 2014
The secret of how salamanders successfully regrow body parts is being unravelled by University College London researchers in a bid to apply it to humans.

Recommended for you

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

3-D mammography detected 34% more breast cancers in screening

October 15, 2018
In traditional mammography screening, all breast tissue is captured in a single image. Breast tomosynthesis, on the other hand, is three-dimensional and works according to the same principle as what is known as tomography. ...

More clues revealed in link between normal breast changes and invasive breast cancer

October 15, 2018
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process—changes in mammary glands to accommodate breastfeeding—uses a molecular process believed ...

Cancer stem cells use 'normal' genes in abnormal ways

October 12, 2018
CDK1 is a "normal" protein—its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well—they present bits of proteins on the surfaces of cells for examination by the immune ...

Obesity linked to increased risk of early-onset colorectal cancer

October 12, 2018
Women who are overweight or obese have up to twice the risk of developing colorectal cancer before age 50 as women who have what is considered a normal body mass index (BMI), according to new research led by Washington University ...

Potential therapy for treatment-resistant hypothyroidism proves effective in lab study

October 12, 2018
A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.